tbc-11251 has been researched along with Pulmonary Fibrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbaro Foschino, MP; Brunetti, ND; Correale, M; Di Biase, M; Lacedonia, D; Montrone, D; Totaro, A | 1 |
| Bellamy, CO; Dhaun, N; Kluth, DC; MacIntyre, IM | 1 |
| Ewert, R; Opitz, CF | 1 |
2 review(s) available for tbc-11251 and Pulmonary Fibrosis
| Article | Year |
|---|---|
Novelty in treatment of pulmonary fibrosis: pulmonary hypertension drugs and others.
Topics: Antihypertensive Agents; Bosentan; Humans; Isoxazoles; Phenylpropionates; Phosphodiesterase Inhibitors; Pulmonary Fibrosis; Pyridazines; Sulfonamides; Thiophenes | 2013 |
Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cell Division; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Isoxazoles; Lung; Pulmonary Fibrosis; Sulfonamides; Thiophenes; Vasoconstriction; Vasodilation | 2006 |
1 other study(ies) available for tbc-11251 and Pulmonary Fibrosis
| Article | Year |
|---|---|
Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney.
Topics: Amides; Antihypertensive Agents; Atrophy; Biomarkers; Biopsy; Endothelin Receptor Antagonists; Female; Fibrosis; Fumarates; Humans; Hypertension, Renal; Isoxazoles; Kidney; Middle Aged; Proteinuria; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Renin; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2009 |